Browse News
Filter News
Found 21 articles
-
Oxular Announces Appointment of Mark Gaffney as Chief Executive Officer
9/11/2023
Oxular Limited , a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announces that Mark Gaffney has been appointed as chief executive officer (CEO) and member of the Board of Directors.
-
Almost two years after its launch, eye-focused gene therapy start-up Vedere Bio II is closing its doors, company leaders announced through a LinkedIn post over the weekend.
-
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
12/19/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023.
-
Foundation Fighting Blindness Announces Leadership Changes
6/21/2022
The Foundation Fighting Blindness announced today the promotions of Jason Menzo to chief executive officer (CEO) of the Foundation and Russell Kelley, PhD, MBA, to managing director of the Retinal Degeneration (RD) Fund, the venture arm of the Foundation, effective July 1, 2022.
-
As the American Society of Gene & Cell Therapy's 25th Annual Meeting wraps up, a host of life science companies touted their research and products. BioSpace looks at some of them.
-
Vedere Bio II Presents Positive New Data Supporting Its Proprietary Platform at the 25th Annual ASGCT Meeting
5/19/2022
Vedere Bio II, Inc. will present new preclinical data at the 25th Annual Meeting of the American Society of Gene and Cell Therapy taking place in Washington, D.C., and virtually, May 16-19, 2022.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Vedere Bio II Appoints Accomplished Clinician and Researcher Anna-Maria Demetriades as Chief Medical Officer
4/26/2022
Vedere Bio II, Inc. today announced the appointment of Anna-Maria Demetriades , M.D., Ph.D. as Chief Medical Officer.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Vedere Bio II Announces Appointment of Industry Veteran Gina Consylman as Chief Financial Officer
4/12/2022
Vedere Bio II, Inc. today announced the appointment of Gina Consylman as Chief Financial Officer.
-
Bayer isn't the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
-
Vedere Bio II Appoints Martina Schinke, Ph.D., as Vice President, Program Leader
2/8/2022
Vedere Bio II, Inc., a company developing next-generation therapies for vision restoration and preservation in patients with vision loss due to photoreceptor death, announced the appointment of Martina Schinke, Ph.D., as Vice President, Program Leader.
-
Novartis believes Gyroscope’s investigational Phase II gene therapy for geographic atrophy has the potential to become the first therapy that demonstrates sustained efficacy for GA patients.
-
BioSpace Movers & Shakers, June 25
6/25/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Vedere Bio II Announces Appointment of Gabor Veres, Ph.D., as Chief Scientific Officer
6/22/2021
Vedere Bio II, Inc., a company developing next-generation ocular gene therapies for vision restoration and preservation in patients with vision loss due to photoreceptor death, announced the appointment of Gabor Veres, Ph.D., as Chief Scientific Officer.
-
The robust $77 million Series A was led by Octagon Capital and the leadership and research team behind the original Vedere Bio.
-
Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
5/18/2021
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness
-
Taysha Gene Therapies Expands Leadership Team with the Appointment of Chief Development Officer
5/13/2021
Mary Newman, former SVP of Regulatory Affairs at Astellas Gene Therapies, joins Taysha with over 30 years of experience in regulatory affairs and research and development in the biotech industry Extensive experience deeply rooted in gene therapy at Astellas Gene Therapies, Audentes Therapeutics and BioMarin
-
Novartis acquired Vedere Bio in a deal totaling up to $280 million. The takeout broadens Novartis’ footprint in gene and cell therapy, with Vedere Bio’s gene therapy platforms for ophthalmic disorders.
-
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company
10/29/2020
Acquisition of Vedere Bio includes lead preclinical intravitreally-injected AAV gene therapy programs focused on pan-genotypic vision restoration in patients with photoreceptor-based vision loss